The detection and therapeutic targeting of MLL as well as JAK2 abnormalities in cases of ALL may be prognostically beneficial as they may represent a distinct subtype of acute lymphoblastic leukemia. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.